[Prostate cancer screening: an update].
Prostate cancer screening using PSA is controversial because of a low specificity and detection of non clinically relevant cancer. Two important studies have been published recently. One of two studies suggests a 20% lowering in specific prostate cancer mortality due to PSA screening. This benefit is relevant but implies at a high risk of overtreatment and treatment-related complications. Currently PSA screening is only proposed as an individual screening for informed patients.
Tawadros
T
T
Service d'urologie, CHUV, Lausanne.
Doerfler
A
A
Treuthardt
C
C
Praz
V
V
Levi
F
F
Zouhair
A
A
Berthold
D
D
Bauer
J
J
Iselin
C
C
Jichlinski
P
P
D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*
D017430:Prostate-Specific Antigen